(Q38101590)

28 August 2017

title

BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies (English)

1 reference

chronic lymphocytic leukemia

28 August 2017

0 references

1 reference

1 reference

1

Tadeusz Robak

1 reference

28 August 2017

2

Pawel Robak

1 reference

28 August 2017

publication date

25 April 2013

1 reference

International Reviews of Immunology

28 August 2017

published in

1 reference

28 August 2017

volume

32

1 reference

28 August 2017

issue

4

1 reference

28 August 2017

page(s)

358-376

1 reference

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Cancer treatment and survivorship statistics, 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Current and emerging treatments for chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Genomic aberrations and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

The tipping points in the initiation of B cell signalling: how small changes make big differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

ITAM-mediated tonic signalling through pre-BCR and BCR complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

The role of the B-cell receptor in the pathogenesis of chronic lymphocytic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Stereotyped B cell receptors in B cell leukemias and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

The B-cell receptor signaling pathway as a therapeutic target in CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

CLL B-cell receptors can recognize themselves: alternative epitopes and structural clues for autostimulatory mechanisms in CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Expression of Bruton's tyrosine kinase protein within the B cell lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Regulation of Btk by Src family tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Binding of Bruton's tyrosine kinase to Fyn, Lyn, or Hck through a Src homology 3 domain-mediated interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Btk function in B cell development and response.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

An important role for Akt3 in platelet activation and thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Measuring PI3K lipid kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

PI3K in lymphocyte development, differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Clinical and immunologic outcome of patients with cartilage hair hypoplasia after hematopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Predictors of competing mortality in advanced head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

The SYK tyrosine kinase: a crucial player in diverse biological functions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Syk and pTyr'd: Signaling through the B cell antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

B cell antigen receptor signaling: roles in cell development and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Targeting the B cell receptor pathway in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Regulation of B-cell fate by antigen-receptor signals

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Targeted drugs in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabinein vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2013.786711

10.3109/08830185.2013.786711

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference